1
|
Merlino A. Metallodrug binding to serum albumin: Lessons from biophysical and structural studies. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2023.215026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
2
|
Troisi R, Galardo F, Ferraro G, Sica F, Merlino A. Cisplatin Binding to Human Serum Transferrin: A Crystallographic Study. Inorg Chem 2023; 62:675-678. [PMID: 36602395 PMCID: PMC9846693 DOI: 10.1021/acs.inorgchem.2c04206] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The molecular mechanism of how human serum transferrin (hTF) recognizes cisplatin at the atomic level is still unclear. Here, we report the molecular structure of the adduct formed upon the reaction of hTF with cisplatin. Pt binds the side chain of Met256 (at the N-lobe), without altering the protein overall conformation.
Collapse
Affiliation(s)
- Romualdo Troisi
- Department
of Chemical Sciences, University of Naples
Federico II, Complesso Universitario di Monte Sant’Angelo, via Cintia, Naples I-80126, Italy
| | - Francesco Galardo
- Department
of Chemical Sciences, University of Naples
Federico II, Complesso Universitario di Monte Sant’Angelo, via Cintia, Naples I-80126, Italy
| | - Giarita Ferraro
- Department
of Chemical Sciences, University of Naples
Federico II, Complesso Universitario di Monte Sant’Angelo, via Cintia, Naples I-80126, Italy
| | - Filomena Sica
- Department
of Chemical Sciences, University of Naples
Federico II, Complesso Universitario di Monte Sant’Angelo, via Cintia, Naples I-80126, Italy
| | - Antonello Merlino
- Department
of Chemical Sciences, University of Naples
Federico II, Complesso Universitario di Monte Sant’Angelo, via Cintia, Naples I-80126, Italy,
| |
Collapse
|
3
|
Teles CM, Lammoglia LC, Juliano MA, Ruiz ALTG, Candido TZ, de Carvalho JE, Lima CSP, Abbehausen C. Novel anticancer Pd II complexes: The effect of the conjugation of transferrin binding peptide and the nature of halogen coordinated on antitumor activity. J Inorg Biochem 2019; 199:110754. [PMID: 31401348 DOI: 10.1016/j.jinorgbio.2019.110754] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 06/14/2019] [Accepted: 06/23/2019] [Indexed: 01/06/2023]
Abstract
A series of PdII complexes with bis-(2-pyridylmethyl)glycine as a ligand of formula [PdX(bis-(2-pyridylmethyl)glycine)] where X = Cl, Br, I were prepared and the effect of the halogen nature in the antitumor activity of eight tumorigenic and one non-tumorigenic cell line was evaluated. The chloride derivative was further functionalized with a transferrin receptor binding peptide, generating the first PdII based metallopeptide. Its antitumor activity was also evaluated. However, among all the complexes, the chloride and iodine parent compounds showed the lowest GI50 values in the panel evaluated, and lowest GI50 than cisplatin in several cell lines. In contrast, the bromine derivative showed higher values of GI50 than chloride and iodine (around 30 - 50 μM). The same trend was observed for the bovine serum albumin binding constant with higher values for iodine, chlorine, and bromine in this order. In aqueous solution, the chloride is exchanged by water while the bromine and iodine are not. DNA was evaluated as a target and showed no significative interaction for all the compounds. The results suggest sulfur-rich proteins and not DNA as a target. This report represents the first PdII metallopeptide reported, its evaluation in solution and antitumor activity. This work opens the possibilities for further functionalization of PdII complexes and the importance of the halogen coordination in the design of novel metallodrugs.
Collapse
Affiliation(s)
- C M Teles
- Institute of Chemistry, University of Campinas - UNICAMP, PO Box 6154, 13083-970 Campinas, SP, Brazil
| | - L C Lammoglia
- Faculty of Pharmaceutical Sciences, University of Campinas, UNICAMP, 13083-871 Campinas, SP, Brazil
| | - M A Juliano
- Universidade Federal de São Paulo, Escola Paulista de Medicina, UNIFESP, 04063-062 São Paulo, SP, Brazil
| | - A L T G Ruiz
- Faculty of Pharmaceutical Sciences, University of Campinas, UNICAMP, 13083-871 Campinas, SP, Brazil
| | - T Z Candido
- Faculty of Medical Sciences, University of Campinas, UNICAMP, 13083-970 Campinas, SP, Brazil
| | - J E de Carvalho
- Faculty of Pharmaceutical Sciences, University of Campinas, UNICAMP, 13083-871 Campinas, SP, Brazil
| | - C S P Lima
- Faculty of Medical Sciences, University of Campinas, UNICAMP, 13083-970 Campinas, SP, Brazil
| | - C Abbehausen
- Institute of Chemistry, University of Campinas - UNICAMP, PO Box 6154, 13083-970 Campinas, SP, Brazil.
| |
Collapse
|
4
|
Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents. APPLIED SCIENCES-BASEL 2017. [DOI: 10.3390/app7010101] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
5
|
Ferraro G, Massai L, Messori L, Merlino A. Cisplatin binding to human serum albumin: a structural study. Chem Commun (Camb) 2016; 51:9436-9. [PMID: 25873085 DOI: 10.1039/c5cc01751c] [Citation(s) in RCA: 99] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The reaction between cisplatin and human serum albumin (HSA) was investigated by X-ray crystallography and crystal structures of the cisplatin/HSA adduct were eventually solved for the first time. Structural data unambiguously prove that cisplatin mainly binds to His105 and Met329 side chains; additional binding sites are detected at His288, Met298, and Met548 and at His535, His67 and His247.
Collapse
Affiliation(s)
- Giarita Ferraro
- Department of Chemical Sciences, University of Naples Federico II, Complesso Universitario di Monte Sant'Angelo, Via Cintia, I-80126, Napoli, Italy.
| | | | | | | |
Collapse
|
6
|
Protein– and Peptide–Drug Conjugates. ADVANCES IN PROTEIN CHEMISTRY AND STRUCTURAL BIOLOGY 2015; 98:1-55. [DOI: 10.1016/bs.apcsb.2014.11.001] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
7
|
Tortorella S, Karagiannis TC. Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy. J Membr Biol 2014; 247:291-307. [DOI: 10.1007/s00232-014-9637-0] [Citation(s) in RCA: 201] [Impact Index Per Article: 20.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 02/11/2014] [Indexed: 12/19/2022]
|
8
|
Abstract
Targeted delivery of anticancer drugs is one of the most actively pursued goals in anticancer chemotherapy. Serum proteins such as transferrin, albumin, and low-density lipoprotein (LDL) offer promise for the selective delivery of antineoplastic agents due to their accumulation in tumor tissue. Uptake of these proteins in solid tumors is mediated by a number of factors, including an increased metabolic activity of tumors, an enhanced vascular permeability of tumor blood vessels for circulating macromolecules, and a lack of a functional lymphatic drainage system in tumor tissue. At the tumor site, transferrin, low-density lipoprotein, and albumin are taken up by the tumor cell through receptor-mediated and fluid phase endocytosis, respectively. Serum protein conjugates can be designed to release the bound antitumor drug after cellular uptake of the drug conjugate. This review covers the diagnostic evidence for tumor accumulation of serum proteins and the design, development, and biological evaluation of drug conjugates with transferrin, albumin, and low-density lipoprotein.
Collapse
Affiliation(s)
- F Kratz
- Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Strasse 117, Freiburg, Federal Republic of Germany.
| | | |
Collapse
|
9
|
Møller C, Tastesen HS, Gammelgaard B, Lambert IH, Stürup S. Stability, accumulation and cytotoxicity of an albumin-cisplatin adduct. Metallomics 2010; 2:811-8. [DOI: 10.1039/c0mt00046a] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
10
|
Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK. Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev 2007; 106:2224-48. [PMID: 16771448 DOI: 10.1021/cr040704h] [Citation(s) in RCA: 523] [Impact Index Per Article: 30.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Andrei R Timerbaev
- Institute of Inorganic Chemistry, University of Vienna, Währinger Strasse 42, A-1090 Vienna, Austria
| | | | | | | |
Collapse
|
11
|
Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 2006; 121:159-76. [PMID: 16920030 DOI: 10.1016/j.clim.2006.06.006] [Citation(s) in RCA: 373] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2006] [Revised: 06/16/2006] [Accepted: 06/16/2006] [Indexed: 10/24/2022]
Abstract
Traditional anti-cancer treatments consist of chemotherapeutic drugs that effectively eliminate rapidly dividing tumor cells. However, in many cases chemotherapy fails to eliminate the tumor and even when chemotherapy is successful, its systemic cytotoxicity often results in detrimental side effects. To overcome these problems, many laboratories have focused on the design of novel therapies that exhibit tumor specific toxicity. The transferrin receptor (TfR), a cell membrane-associated glycoprotein involved in iron homeostasis and cell growth, has been explored as a target to deliver therapeutics into cancer cells due to its increased expression on malignant cells, accessibility on the cell surface, and constitutive endocytosis. The TfR can be targeted by direct interaction with conjugates of its ligand transferrin (Tf) or by monoclonal antibodies specific for the TfR. In this review we summarize the strategies of targeting the TfR in order to deliver therapeutic agents into tumor cells by receptor-mediated endocytosis.
Collapse
Affiliation(s)
- Tracy R Daniels
- Division of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
| | | | | | | |
Collapse
|
12
|
Rudnev AV, Aleksenko SS, Semenova O, Hartinger CG, Timerbaev AR, Keppler BK. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. J Sep Sci 2005; 28:121-7. [PMID: 15754818 DOI: 10.1002/jssc.200401930] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
A CE method has been developed to evidence and quantitatively characterize the interaction between platinum-based antitumor drugs and human serum proteins. This method is a variant of affinity CE modified regarding both experimental setup and data treatment so as to measure the peaks (or vacancies) that correspond to the bound drug when it slowly binds to the protein. Using the formalism of the Hummel-Dreyer method and cisplatin and oxaliplatin as test compounds, a protocol for determining albumin and transferrin binding constants and stoichiometries, including (and distinguished by) 48 hours of incubation of the reaction mixture, was elaborated. Relative affinities of drugs toward different proteins in aqueous solution at physiological pH, chloride concentration, and temperature were compared in terms of overall binding constants and numbers of drug molecules attached to the protein. The results indicate that both platinum drugs bind to albumin more strongly than to transferrin, supporting the concept that the albumin fraction is a major drug supply route for chemotherapeutical needs. From a comparison with the binding parameters measured previously for cisplatin by other methods, conclusions were drawn about the validity of CE as a simple and convenient method for assaying protein-drug reactions with slow kinetics.
Collapse
Affiliation(s)
- Alexander V Rudnev
- Vernadsky Institute of Geochemistry and Analytical Chemistry, Russian Academy of Sciences, 117975 Moscow, Russia
| | | | | | | | | | | |
Collapse
|
13
|
Zhao YY, Mandal R, Li XF. Intact human holo-transferrin interaction with oxaliplatin. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2005; 19:1956-62. [PMID: 15954173 DOI: 10.1002/rcm.2010] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
We report the interaction of intact human holo-transferrin (holo-Tf) with oxaliplatin (an anticancer drug), and the characterization of a complex composed of (1:1) intact holo-Tf and the parent oxaliplatin molecule using nanoelectrospray ionization quadrupole time-of-flight mass spectrometry (nanoESI-QTOF-MS). The molecular weight of this complex was determined to be 80,077 Da, which was an increase of 397 mass units compared to the protein alone (79,680 Da), suggesting that a parent drug molecule was bound to the intact protein. We further examined the interaction between the intact protein and oxaliplatin using size-exclusion high-performance liquid chromatography/inductively coupled plasma mass spectrometry (HPLC/ICPMS). The protein complex and free oxaliplatin were separated by HPLC and quantitatively determined by simultaneous monitoring of both 195Pt and 56Fe using ICPMS. The HPLC/ICPMS detected both Pt and Fe signals at retention time of 2.6 min, identifying the protein-drug complex. The Fe signal at 2.6 min did not change with the increase in incubation time of the reaction mixture containing holo-Tf and oxaliplatin, while the Pt signal at the same retention time increased over time, further demonstrating that the formation of this complex does not affect the protein-bound Fe. The binding constant of the (1:1) intact human holo-Tf-oxaliplatin complex was determined to be 7.7x10(5) M-1. Both nanoESI-MS and HPLC/ICPMS results support that the holo-Tf and parent oxaliplatin molecules form complexes through non-covalent binding, suggesting that holo-Tf may be a useful carrier for oxaliplatin delivery.
Collapse
Affiliation(s)
- Yuan-Yuan Zhao
- Environmental Health Sciences, Department of Public Health Sciences, Faculty of Medicine and Dentistry, University of Alberta, Canada T6G 2G3
| | | | | |
Collapse
|
14
|
Jakupec MA, Galanski MS, Keppler BK. Tumour-inhibiting platinum complexes--state of the art and future perspectives. Rev Physiol Biochem Pharmacol 2003; 146:1-54. [PMID: 12605304 DOI: 10.1007/s10254-002-0001-x] [Citation(s) in RCA: 308] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Thirty years after the onset of the first clinical studies with cisplatin, the development of antineoplastic platinum drugs continues to be a productive field of research. This article reviews the current preclinical and clinical status, including a discussion of the molecular basis for the activity of the parent drug cisplatin and platinum drugs of the second and third generation, in particular their interaction with DNA. Further emphasis is laid on the development of third generation platinum drugs with activity in cisplatin-resistant tumours, particularly on chelates containing 1,2-diaminocyclohexane (DACH) and on the promising and more recently evolving field of non-classic ( trans- and multinuclear) platinum complexes. The development of oral platinum drugs and drug targeting strategies using liposomes, polymers or low-molecular-weight carriers in order to improve the therapeutic index of platinum chemotherapy are also covered.
Collapse
Affiliation(s)
- M A Jakupec
- Institute of Inorganic Chemistry, University of Vienna, Währinger Strasse 42, 1090, Vienna, Austria
| | | | | |
Collapse
|
15
|
Tanaka T, Fujishima Y, Kaneo Y. Receptor mediated endocytosis and cytotoxicity of transferrin-mitomycin C conjugate in the HepG2 cell and primary cultured rat hepatocyte. Biol Pharm Bull 2001; 24:268-73. [PMID: 11256483 DOI: 10.1248/bpb.24.268] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Intracellular disposition and cytotoxicity of macromolecular conjugate of mitomycin C (MMC) with transferrin (TF) were examined in the human hepatoma cell line HepG2 cell and normal cultured rat hepatocyte. The conjugate (TF-MMC) was specifically bound to the HepG2 cell as well as TF. The number of the binding site and the association constant of TF-MMC in the HepG2 cell were 396000+/-31000 molecules/cell and 3.24 x 10(7)+/-0.58 x 10(7) M(-1), respectively. No difference in the binding parameters of TF-MMC and TF can be detected in the HepG2 cell. The association constant for the TF receptor was almost identical between HepG2 cell and hepatocyte, however, the numbers of the binding site of TF-MMC and TF in the HepG2 cell were from 40-times to 50-times greater than those in the hepatocyte. Furthermore, TF-MMC was internalized into the HepG2 cell and the hepatocyte as well as TF. The rates of internalization of TF-MMC and TF into the HepG2 cell were nearly identical to those into the hepatocyte. However, the levels of the internalization into the HepG2 cell were remarkably higher than those into the hepatocyte because the number of receptors in the HepG2 cell was larger than that in the hepatocyte, and the rate of release from the HepG2 cell was slower than that from the hepatocyte. TF-MMC inhibited the growth of the HepG2 cells. The 50% growth inhibition (GI50) of TF-MMC against the HepG2 cell was 0.9 microg MMC/ml, which was a little higher than that of MMC (GI50=0.5 microg/ml). These results indicated that the TF-MMC might be useful for delivery of MMC to the HepG2 cell.
Collapse
Affiliation(s)
- T Tanaka
- Department of Biopharmaceutics, Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.
| | | | | |
Collapse
|
16
|
Watanabe T, Takano M, Ogasawara A, Mikami T, Kobayashi T, Watabe M, Matsumoto T. Anti-Candida activity of a new platinum derivative. Antimicrob Agents Chemother 2000; 44:2853-4. [PMID: 10991871 PMCID: PMC90162 DOI: 10.1128/aac.44.10.2853-2854.2000] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A new platinum derivative of the form H[Pt(IV)(Hdigly)Cl(2)(OH)(2)] (Hdigly==glycylglycine) damaged the Candida albicans cell membrane and inhibited the growth of the cells. The cytotoxic activity of H[Pt(IV)(Hdigly)Cl(2)(OH)(2)] on mammalian cells was 10-fold lower than that of cis-diammine-dichloroplatinum (cisplatin). Substitution of platinum for peptides is effective for enhancement of antifungal activity and reduction of the toxicity to mammalian cells.
Collapse
Affiliation(s)
- T Watanabe
- Department of Microbiology, Tohoku Pharmaceutical University, Sendai 981-8558, Japan
| | | | | | | | | | | | | |
Collapse
|
17
|
Dufes C, Schätzlein AG, Tetley L, Gray AI, Watson DG, Olivier JC, Couet W, Uchegbu IF. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm Res 2000; 17:1250-8. [PMID: 11145231 DOI: 10.1023/a:1026422915326] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
PURPOSE To prepare polymeric vesicles and niosomes bearing glucose or transferrin ligands for drug targeting. METHODS A glucose-palmitoyl glycol chitosan (PGC) conjugate was synthesised and glucose-PGC polymeric vesicles prepared by sonication of glucose-PGC/cholesterol. N-palmitoylglucosamine (NPG) was synthesised and NPG niosomes also prepared by sonication of NPG/ sorbitan monostearate/ cholesterol/ cholesteryl poly-24-oxyethylene ether. These 2 glucose vesicles were incubated with colloidal concanavalin A gold (Con-A gold), washed and visualised by transmission electron microscopy (TEM). Transferrin was also conjugated to the surface of PGC vesicles and the uptake of these vesicles investigated in the A431 cell line (over expressing the transferrin receptor) by fluorescent activated cell sorter analysis. RESULTS TEM imaging confirmed the presence of glucose units on the surface of PGC polymeric vesicles and NPG niosomes. Transferrin was coupled to PGC vesicles at a level of 0.60+/-0.18 g of transferrin per g polymer. The proportion of FITC-dextran positive A431 cells was 42% (FITC-dextran solution), 74% (plain vesicles) and 90% (transferrin vesicles). CONCLUSIONS Glucose and transferrin bearing chitosan based vesicles and glucose niosomes have been prepared. Glucose bearing vesicles bind Con-A to their surface. Chitosan based vesicles are taken up by A431 cells and transferrin enhances this uptake.
Collapse
Affiliation(s)
- C Dufes
- Department of Pharmaceutical Sciences, University of Strathclyde, Strathclyde Institute for Biomedical Sciences, Glasgow, United Kingdom
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Takada K, Kawamura T, Inai M, Masuda S, Oka T, Yoshikawa Y, Shibata N, Yoshikawa H, Ike O, Wada H, Hitomi S. Pharmacokinetics of cisplatin in analbuminemic rats. Biopharm Drug Dispos 1999; 20:421-8. [PMID: 10951431 DOI: 10.1002/1099-081x(199912)20:9<421::aid-bdd206>3.0.co;2-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The effect of protein binding on the pharmacokinetics of cisplatin (cis-diamminedichloroplatinum (II); CDDP) has been studied in analbuminemic rats, which genetically lack albumins, in comparison with normal rats. CDDP was reported to highly bind to serum components, and the major binder was thought to be an albumin. However, there were no significant differences in the serum disappearance profiles of platinum after intravenous (iv) bolus injection of CDDP to analbuminemic rats as compared with normal rats. The total body clearance, Cl(tot), of platinum in normal rats was 48.7+/-22.0 mL h(-1) (5 mg kg(-1)), 55.9+/-4.04 mL h(-1) (10 mg kg(-1)) and 49.0+/-3.57 mL h(-1) (20 mg kg(-1)), whereas Cl(tot) in analbuminemic rats was 52.0+/-8.48 mL h(-1) (5 mg kg(-1)), 62.9+/-10. 8 mL h(-1) (10 mg kg(-1)) and 62.8+/-6.81 mL h(-1) (20 mg kg(-1)). The serum blood urea nitrogen (BUN) and creatinine levels at 6 h after iv injection were higher in both groups of rats who received CDDP than those of pre-dose level. However, there were no significant differences in the renal function tests between analbuminemic rats and normal rats. The binding of CDDP to the serum samples obtained from analbuminemic rats and normal rats was measured by a centrifuging filtration method. The binding percentages were 68.0+/-5.9% (2.0 microg mL(-1)), 56.8+/-4.1% (5.0 microg mL(-1)) and 64.6+/-4.4% (10.0 microg mL(-1)) in analbuminemic rats and 52.9+/-3.5% (2.0 microg mL(-1)), 52.2+/-3.4% (5.0 microg mL(-1)), 56.9+/-1.9% (10.0 microg mL(-1)) in normal rats. Higher binding percentages were obtained in analbuminemic rats than in normal rats. In vitro binding studies under the two incubation conditions (5 min and 2 h) showed that the binding percentages of CDDP to serum proteins were 59.2+/-3.2% (5 min) and 72.3+/-6.5% (2 h) for albumin, 42.3+/-1.9% (5 min) and 39.5+/-2.5% (2 h) for alpha(1)-acid glycoprotein (AAG) and 51.7+/-5.3% (5 min) and 49. 2+/-1.9% (2 h) for gamma-globulin. From these studies, it was elucidated that albumin is not the major ligand in the rat serum and that other proteins also have important roles in the pharmacokinetics of CDDP.
Collapse
Affiliation(s)
- K Takada
- Department of Pharmacokinetics, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Kodaka M, Dohta Y, Rekonen P, Okada T, Okuno H. Physicochemical factors for cytotoxic activity in platinum dinuclear complexes with pyrimidine and imide ligands. Biophys Chem 1998; 75:259-70. [PMID: 9894342 DOI: 10.1016/s0301-4622(98)00213-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The relationship between cytotoxic activity of platinum dinuclear complexes toward cancer cells and their intrinsic properties (electrophilicity and hydrophobicity) have been examined. It is shown that the reactivity with chloride anion is a good index of the electrophilicity of the platinum complexes. By assuming a cell kill pharmacodynamic model, the relation between IC50 value and the electrophilicity is obtained. It is concluded that inside cells the reactivity of the platinum complexes having imide ligands is higher than that of CDDP. The other important factor which affects the cytotoxic activity is hydrophobicity. The log k' values (k': capacity factor) are found useful to estimate the hydrophobicity of platinum complexes. The accumulation of platinum into cells is dominated by the hydrophobicity and the charge of platinum complexes. Highly hydrophobic complexes are thought to be adsorbed in cell membranes, resulting in low cytotoxic activity since they cannot reach DNA. A schematic model of the interaction between platinum complexes and serum proteins reveals that more hydrophobic complexes tend to bind to serum proteins more stably. At least three possible paths of the cellular platinum accumulation are suggested: direct accumulation of the platinum complexes, incorporation in the form of CDDP produced from the complexes, and incorporation through protein-platinum complexes, although the contribution of the third one may be small.
Collapse
Affiliation(s)
- M Kodaka
- Biomolecules Department, National Institute of Bioscience and Human-Technology, Ibaraki, Japan.
| | | | | | | | | |
Collapse
|
20
|
Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ. Cisplatin binding sites on human albumin. J Biol Chem 1998; 273:14721-30. [PMID: 9614070 DOI: 10.1074/jbc.273.24.14721] [Citation(s) in RCA: 274] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Reactions of cisplatin (cis-[PtCl2(NH3)2]) with albumin are thought to play an important role in the metabolism of this anticancer drug. They are investigated here via (i) labeling of cisplatin with 15N and use of two-dimensional 1H,15N NMR spectroscopy, (ii) comparison of natural human serum albumin with recombinant human albumin (higher homogeneity and SH content), (iii) chemical modification of Cys, Met, and His residues, (iv) reactions of bound platinum with thiourea, and (v) gel filtration chromatography. In contrast to previous reports, it is shown that the major sulfur-containing binding site involves Met and not Cys-34, and also a N ligand, in the form of an S,N macrochelate. Additional monofunctional adducts involving other Met residues and Cys-34 are also observed. During the later stages of reactions of cisplatin with albumin, release of NH3 occurs due to the strong trans influence of Met sulfur, which weakens the Pt-NH3 bonds, and protein cross-linking is observed. The consequences of these findings for the biological activity of cisplatin-albumin complexes are discussed.
Collapse
Affiliation(s)
- A I Ivanov
- Department of Chemistry, University of Edinburgh, Edinburgh EH9 3JJ, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
21
|
Head JF, Wang F, Elliott RL. Antineoplastic drugs that interfere with iron metabolism in cancer cells. ADVANCES IN ENZYME REGULATION 1997; 37:147-69. [PMID: 9381969 DOI: 10.1016/s0065-2571(96)00010-6] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Normal iron metabolism can be perturbed with iron chelators, toxic metals that bind to transferrin, toxic metals bound to transferrin or antineoplastic agents covalently linked to transferrin. These agents cause significant inhibition of tumor cell growth in cell culture and have been shown to have significant in vivo antineoplastic activity. Cell culture studies showed that deferoxamine mesylate inhibits cell growth and division in both the MCF-7 human breast and HeLa human cervical carcinoma cell lines. Animal studies demonstrated that when deferoxamine mesylate is injected intravenously into rats that are on a low iron diet, there is a significant reduction in the growth of 13762NF mammary adenocarcinomas. Gallium, indium and the antineoplastic agent cisplatin were bound to the iron binding site of transferrin and inhibit the growth of malignant carcinoma cell lines. Gallium-transferrin and indium-transferrin were at least 10 times more inhibitory to both MCF-7 and HeLa cell lines than their free salts. Further cell culture studies demonstrated that cisplatin-transferrin complexes act synergistically with doxorubicin to inhibit the growth of cultured MCF-7 cells. In a Phase I clinical trial of cisplatin-transferrin complex there was a 36% (four of 11 patients) response rate in breast cancer patients with advanced disease. In a second clinical study the sequential administration of deferoxamine mesylate (2 days at 6 g/day in 8 hrs), cisplatin-transferrin complex (7 days at 500 mg/day) and FAC (5-fluorouracil, doxorubicin and cyclophosphamide at 450, 45 and 450 mg/m2, respectively) to advanced breast cancer patients resulted in partial responses in seven of eight patients treated. Future work will concentrate on substituting transferrin based agents with daunorubicin or doxorubicin attached to the surface of the transferrin, and gallium or indium bound to the iron binding site, to increase efficacy of the second component of the sequential combination chemotherapy.
Collapse
Affiliation(s)
- J F Head
- Mastology Research Institute, Elliott Mastology Center, Baton Rouge, LA 70816, USA
| | | | | |
Collapse
|
22
|
Hoshino T, Misaki M, Yamamoto M, Shimizu H, Ogawa Y, Toguchi H. Receptor-binding, in vitro cytotoxicity, and in vivo distribution of transferrin-bound cis-platinum (II) of differing molar ratios. J Control Release 1995. [DOI: 10.1016/0168-3659(95)00066-h] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|